CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) engineered to resist proteolytic degradation while retaining full agonist activity at the GHRH receptor (GHRHR). The compound has become one of the most studied growth hormone secretagogues in peptide research, both as a standalone tool for GH axis investigation and as a combination partner with ghrelin-mimetic peptides such as Ipamorelin. This review examines the molecular design rationale behind CJC-1295, its receptor pharmacology, half-life engineering via Drug Affinity Complex (DAC) technology, and its established role in in vitro and preclinical research models.
Molecular Design and Half-Life Engineering
Native GHRH (1-44) has a plasma half-life of approximately 7 minutes, rendered short by dipeptidyl peptidase-IV (DPP-IV) cleavage at the Ala2 position and non-specific serum protease activity. CJC-1295 addresses this limitation through two structural modifications. First, it incorporates a Ala2 → substitution that eliminates the primary DPP-IV cleavage site. Second, the DAC version (CJC-1295 DAC) incorporates a maleimido-propionic acid (MPA) linker at the C-terminus that forms a covalent bond with serum albumin’s Cys34 residue upon systemic exposure, extending the effective half-life to 6-8 days and enabling sustained GH pulsatility elevation in research models.
The non-DAC version of CJC-1295 (often referred to as modified GRF 1-29 or Mod-GRF) retains the DPP-IV-resistant modifications but lacks the albumin-binding linker, producing a half-life of approximately 30 minutes, substantially longer than native GHRH but shorter than the DAC variant. This distinction is experimentally relevant: non-DAC CJC-1295 more closely mimics physiological GHRH pulse kinetics, making it the preferred tool for studies examining acute GH release dynamics, while DAC-CJC-1295 produces sustained GH elevation suitable for chronic elevation studies. Stackpure offers CJC-1295 DAC and CJC-1295 No DAC in research vial format for qualified investigators.
GHRH Receptor Pharmacology
The growth hormone-releasing hormone receptor (GHRHR) is a class B G-protein coupled receptor (GPCR) coupled to Gs proteins. CJC-1295 binds the GHRHR with high affinity, triggering adenylyl cyclase activation, cAMP accumulation, and protein kinase A (PKA) activation in somatotroph cells of the anterior pituitary. This signalling cascade converges on CREB phosphorylation and subsequent transcriptional activation of GH gene expression. Simultaneously, elevated cAMP promotes Ca2+ influx through voltage-gated calcium channels, triggering exocytosis of stored GH from somatotrophic secretory granules.
Critically, CJC-1295 operates within the hypothalamic-pituitary GH axis without overriding physiological feedback mechanisms. GH secretion remains subject to somatostatin (SRIF) inhibition from the hypothalamus, meaning CJC-1295 amplifies GH pulse amplitude rather than inducing tonic, non-pulsatile elevation. This property is of particular research value in studies examining GH axis dysregulation in aging models, where attenuated GH pulsatility is a characteristic finding independent of pituitary cell number.
Ipamorelin Combination Protocols
The most extensively studied combination in GH secretagogue research pairs CJC-1295 with a ghrelin-axis agonist, most commonly Ipamorelin. The mechanistic rationale is complementary signalling: CJC-1295 activates the GHRHR (Gs-coupled, cAMP-mediated), while Ipamorelin activates the growth hormone secretagogue receptor (GHSR-1a, Gq-coupled, PKC-mediated). The two pathways converge at the level of somatotroph GH secretion but involve distinct second messenger systems, producing a synergistic rather than merely additive effect on GH release in preclinical studies.
Research by Andersen et al. (2014, Journal of Clinical Endocrinology) examining GHRH/ghrelin axis interactions demonstrated that co-administration of GHRH analogues with ghrelin-mimetics produced GH responses substantially greater than either compound alone, particularly in aged animal models where somatostatin tone is elevated and pituitary responsiveness is reduced. This synergistic profile has made the CJC-1295/Ipamorelin combination the dominant GH axis research protocol in contemporary preclinical work. Stackpure provides this combination as a pre-formulated CJC-1295/Ipamorelin Blend or as individual vials for researchers preferring independent dosing control.
Downstream IGF-1 Axis Effects
In preclinical models, sustained GH elevation via CJC-1295 DAC administration produces measurable increases in hepatic IGF-1 production, the primary downstream effector of GH anabolic signalling. IGF-1 acts at the IGF-1R (a receptor tyrosine kinase) to activate PI3K/Akt and MAPK/ERK pathways, mediating effects on protein synthesis, cell proliferation, and glucose metabolism. Research using DAC-CJC-1295 in rodent aging models (Johannsson et al.) demonstrated dose-dependent increases in serum IGF-1 that correlated with improvements in lean mass parameters and skeletal muscle protein synthesis rates.
The IGF-1 elevation produced by CJC-1295 is distinct from exogenous IGF-1 administration in its kinetics: GH-stimulated IGF-1 production is hepatically derived and subject to IGF-binding protein (IGFBP) regulation, producing a more physiological bioavailability profile than direct IGF-1R agonism. This distinction is relevant when designing studies to dissect GH-dependent versus GH-independent IGF-1R signalling contributions. For researchers interested in direct IGF-1 pathway research tools, Stackpure also offers IGF-1 LR3 and IGF-1 DES as complementary research compounds.
Research Applications: Aging, Body Composition, and Metabolism
CJC-1295’s primary research applications span three interconnected domains. In aging biology, it serves as a tool to reverse the somatotrophic deficiency characteristic of the aging pituitary, enabling researchers to model GH restoration and examine downstream effects on body composition, cognitive function markers, and inflammatory cytokine profiles. In body composition research, CJC-1295/Ipamorelin protocols in rodent models have demonstrated reductions in adipose tissue mass and preservation of lean mass in caloric restriction paradigms. In metabolic research, the interaction between GH pulsatility and insulin sensitivity is a key variable, GH is a counter-regulatory hormone that induces transient insulin resistance, and CJC-1295 protocols provide a controlled means to manipulate GH exposure in metabolic studies.
CJC-1295 is also used in research examining pituitary reserve, the functional capacity of somatotroph cells to secrete GH in response to stimulation. As a GHRHR agonist with defined pharmacokinetics, it provides a more reproducible stimulation test than insulin tolerance testing (ITT) in preclinical GH reserve assessment models.
Frequently Asked Questions
What is the difference between CJC-1295 DAC and CJC-1295 No DAC?
CJC-1295 DAC incorporates a Drug Affinity Complex linker that enables covalent albumin binding, extending half-life to 6-8 days and producing sustained GH elevation. CJC-1295 No DAC (Mod-GRF 1-29) lacks this modification, producing a half-life of approximately 30 minutes, more suitable for acute GH pulsatility research. The choice depends on whether the research model requires chronic elevation or acute pulse simulation.
Is CJC-1295 the same as Sermorelin?
No. Sermorelin is GHRH(1-29), the shortest biologically active GHRH fragment, with a half-life of approximately 10-15 minutes. CJC-1295 No DAC incorporates additional structural modifications at positions 2, 8, 15, and 27 that confer DPP-IV resistance, approximately doubling half-life versus Sermorelin. CJC-1295 DAC further extends this via albumin binding. Both act at the GHRHR but with substantially different pharmacokinetic profiles.
What purity standard does Stackpure use for CJC-1295?
Stackpure’s CJC-1295 products are manufactured to +99% purity as verified by HPLC analysis, with mass spectrometry confirmation of molecular identity. Certificates of Analysis are available for every production batch through the Lab Testing Standards page.